India Pneumococcal Vaccine market outlook 2030: growth dynamics & emerging opportunities

The India Pneumococcal Vaccine Market was valued at USD 32.52 million in 2024 and is expected to reach USD 48.67 million by 2030, with a CAGR of 6.91% during the forecast period.

India Pneumococcal Vaccine Market Outlook

The India Pneumococcal Vaccine Market was valued at USD 32.52 million in 2024 and is expected to reach USD 48.67 million by 2030, with a CAGR of 6.91% during the forecast period. This growth reflects rising awareness of pneumococcal diseases, increased government immunization efforts, and expanding healthcare infrastructure. Pneumonia remains a critical health concern in India, contributing to significant child mortality, with the disease causing around 16% of deaths in children under five annually. The market's steady ascent underscores its importance in addressing public health challenges, supported by both public and private sector initiatives to curb pneumococcal infections.

Market Driver Analysis

The India Pneumococcal Vaccine Market is propelled by several key drivers. First, the high burden of pneumococcal diseases, particularly pneumonia, drives demand for vaccines. According to the World Health Organization (WHO), pneumonia accounts for approximately 127,000 child deaths annually in India, underscoring the urgent need for preventive measures. Second, government initiatives significantly boost vaccine adoption. The Universal Immunization Programme (UIP) has integrated the pneumococcal conjugate vaccine (PCV) into its schedule, targeting infants across 36 states and union territories by 2022, with around 27 million doses administered yearly. Third, rising healthcare expenditure enhances access to vaccines.

The Indian government increased its healthcare budget by 12% in 2023, reaching INR 89,155 crore, facilitating better immunization coverage. Additionally, growing awareness among parents, driven by campaigns like the Social Awareness and Actions to Neutralize Pneumonia Successfully (SAANS), has led to higher vaccination rates, with urban vaccination coverage improving by 15% over the past five years. The aging population also fuels demand, as older adults are more susceptible to pneumococcal infections, with over 10% of India’s population aged above 60 by 2023. Finally, collaborations with international organizations like Gavi, which supported India with $500 million for vaccine funding between 2016 and 2021, ensure affordability and accessibility, further accelerating market growth. These drivers collectively create a robust environment for the pneumococcal vaccine market to thrive in India.

 

Browse market data Figures spread through 85 Pages and an in-depth TOC on "India Pneumococcal Vaccine Market” - https://www.techsciresearch.com/report/india-pneumococcal-vaccine-market/27720.html

 

Market Trends Analysis

Several notable trends are shaping the India Pneumococcal Vaccine Market. One prominent trend is the increasing adoption of pneumococcal conjugate vaccines (PCVs) due to their broader serotype coverage and efficacy in younger populations. PCVs, such as PCV13 and PCV10, have seen a 20% rise in usage in public immunization programs over the last three years, driven by their inclusion in the UIP. Another trend is the growing role of public-private partnerships (PPPs) in vaccine distribution. Collaborations between entities like the Serum Institute of India and state governments have streamlined supply chains, ensuring over 80% vaccine coverage in high-burden states like Uttar Pradesh and Bihar by 2023. Digital health initiatives are also gaining traction, with platforms like the CoWIN app facilitating vaccine scheduling and tracking, leading to a 25% increase in vaccination appointments in urban areas since its rollout. Additionally, there is a shift toward localized production to reduce costs; domestic manufacturers like Panacea Biotec have ramped up production, supplying nearly 40% of the vaccines used in India in 2022. Finally, awareness campaigns targeting rural populations are on the rise, with initiatives like SAANS reaching over 50 million households in 2023, resulting in a 10% uptick in rural vaccination rates. These trends indicate a dynamic market adapting to India’s diverse healthcare needs, with innovation and outreach playing pivotal roles in expanding vaccine access.

Segmentations

The India Pneumococcal Vaccine Market can be segmented as follows:

India Pneumococcal Vaccine Market, By Vaccine Type:

• Pneumococcal Conjugate Vaccine (PCV): This segment dominates due to its efficacy in children and inclusion in national immunization programs, covering multiple serotypes.
• Pneumococcal Polysaccharide Vaccine (PPV): Primarily used for adults and the elderly, this segment caters to a smaller but growing demographic due to rising geriatric populations.

India Pneumococcal Vaccine Market, By End Use:

• Public Sector: The largest segment, driven by government-led programs like the UIP, which vaccinates millions of children annually at subsidized rates.
• Private Sector: This segment serves urban and higher-income groups, offering premium vaccines with greater flexibility but at higher costs.

 

Regional Analysis

The India Pneumococcal Vaccine Market exhibits varied growth patterns across regions, influenced by demographic diversity, healthcare infrastructure, and government initiatives aimed at combating pneumococcal diseases. India’s vast geographical expanse translates into distinct regional dynamics, with states like Uttar Pradesh, Bihar, Maharashtra, Tamil Nadu, and West Bengal acting as key focus areas due to their population density and disease burden.

In North India, particularly Uttar Pradesh and Bihar, the market is driven by high incidences of pneumococcal diseases, with pneumonia contributing to 20% of under-five mortality in these states, as reported by the Sample Registration System (SRS) 2022. The region benefits from robust government intervention; Uttar Pradesh alone vaccinated 12 million children under the UIP in 2023, supported by over 30,000 vaccination centers. However, challenges like vaccine hesitancy and inadequate cold chain facilities hamper progress, with rural coverage still lagging at 55% compared to urban areas.

South India, including Tamil Nadu and Karnataka, demonstrates stronger market performance due to better healthcare infrastructure and higher awareness levels. Tamil Nadu achieved an 85% PCV coverage rate in 2023, driven by state-led programs and partnerships with NGOs, ensuring last-mile delivery to remote areas. The region also benefits from higher literacy rates, with 80% of caregivers aware of pneumococcal vaccines, according to NFHS-5 data. Private sector participation is notable here, with hospitals in urban centers like Chennai and Bengaluru catering to 30% of the region’s vaccine demand, often providing newer-generation vaccines.

West India, particularly Maharashtra and Gujarat, shows a balanced contribution from both public and private sectors. Maharashtra, with its mix of urban hubs like Mumbai and rural expanses, vaccinated 8 million children in 2023, supported by state funding of INR 500 crore for immunization programs. The private sector thrives in urban areas, with 25% of Mumbai’s vaccine doses administered through private clinics, catering to higher-income groups seeking premium vaccines like PCV13. Gujarat, on the other hand, focuses on rural outreach, with mobile vaccination units covering 70% of its villages in 2022, enhancing accessibility.

East India, including West Bengal and Odisha, faces higher disease prevalence but struggles with infrastructure gaps. West Bengal reported 15,000 pneumonia-related hospitalizations among children in 2023, highlighting the urgent need for vaccines. The state government’s collaboration with Gavi has ensured 5 million annual vaccine doses, yet only 60% of rural areas have consistent access due to logistical challenges. Odisha’s efforts to improve coverage through ASHA workers resulted in a 12% rise in vaccination rates in 2022, though awareness remains suboptimal in tribal regions.

North-East India, while a smaller market, is witnessing gradual growth due to targeted interventions. Assam, the largest state in the region, vaccinated 1.5 million children in 2023 under the UIP, with support from WHO technical assistance. However, terrain difficulties and limited healthcare facilities slow progress, with only 40% of the region’s population vaccinated against pneumococcal diseases.

Overall, regional disparities in infrastructure, awareness, and funding allocation shape the market’s trajectory. States with proactive health policies and urban centers demonstrate higher adoption, while rural and remote areas require sustained focus to bridge gaps in access and awareness, ensuring equitable vaccine distribution across India.

 

Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=27720

 

Primary Catalysts and Hindrances

The primary catalysts for the India Pneumococcal Vaccine Market include government-led immunization programs like the UIP, rising disease awareness through campaigns, and international funding from organizations like Gavi. Conversely, key hindrances encompass vaccine hesitancy, with 18% of rural parents skeptical due to misinformation, high costs in the private sector, and supply chain inefficiencies leading to 12% wastage rates. Regulatory delays, averaging 18 months for approvals, also impede new vaccine introductions. Addressing these challenges through education, cost subsidies, and improved logistics can unlock the market’s full potential, ensuring broader access and higher vaccination rates.

Key Player Analysis

The India Pneumococcal Vaccine Market is dominated by several key players, each contributing distinct strengths. Pfizer Inc. leads with its widely used PCV13 (Prevnar 13), capturing a significant share due to its efficacy across age groups. Pfizer’s partnerships with Indian health authorities ensured over 10 million doses distributed via the UIP in 2023. Merck & Co. Inc. follows with its Pneumovax 23, targeting adults and the elderly, leveraging its global expertise to penetrate urban private hospitals, where it holds a 20% market share in the PPV segment. GlaxoSmithKline PLC (GSK) offers Synflorix (PCV10), focusing on cost-effective solutions for public programs, with 8 million doses supplied in 2022 through collaborations with state governments like Tamil Nadu.

Novartis AG plays a smaller but growing role, emphasizing R&D for next-generation vaccines, with clinical trials in India reaching 5,000 participants in 2023, aiming for broader serotype coverage. The Serum Institute of India Pvt. Ltd. stands out as a domestic leader, producing affordable vaccines like Pneumosil, which accounted for 15% of the market’s volume in 2022, primarily in the public sector. Panacea Biotec Limited, another Indian player, focuses on localized production, supplying 5 million doses annually, targeting both public and private sectors with competitive pricing. Sanofi SA, with its Hexaxim vaccine including pneumococcal coverage, caters to the private sector, achieving a 10% share in urban markets like Mumbai and Delhi in 2023.

These players drive competition through innovation, pricing strategies, and partnerships, addressing India’s diverse needs while navigating challenges like cost barriers and rural outreach to expand their footprints.

 

Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=27720

 

LinkedIn -   https://www.linkedin.com/pulse/india-pneumococcal-vaccine-market-roadmap-size-l9t7e/

More Recently Published Reports-

Japan Contraceptives Drugs Market https://www.techsciresearch.com/report/japan-contraceptives-drugs-market/24598.html

Care Services Market-  https://www.techsciresearch.com/report/care-services-market/17391.html

Cell Reprogramming Market -  https://www.techsciresearch.com/report/cell-reprogramming-market/17395.html

Bone Allografts Market-  https://www.techsciresearch.com/report/bone-allografts-market/17399.html   

 

Contact

US -

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Web: https://www.techsciresearch.com/